Search
Descriptor English: Dasatinib
Descriptor Spanish: Dasatinib
Descriptor dasatinib
Scope note: ANTINEOPLÁSICO derivado de la pirimidina y del tiazol e INHIBIDOR DE PROTEÍNA QUINASA de las PROTEÍNAS DE FUSIÓN BCR-ABL. Se utiliza en el tratamiento de pacientes con LEUCEMIA MIELOIDE CRÓNICA que son resistentes o intolerantes a IMATINIB.
Descriptor Portuguese: Dasatinibe
Descriptor French: Dasatinib
Entry term(s): (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
354825, BMS
BMS 354825
BMS-354825
BMS354825
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
Tree number(s): D02.886.675.184
D03.383.129.708.198
D03.383.742.148
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000069439
Scope note: A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antineoplastic Agents
Protein Kinase Inhibitors
Registry Number: RBZ1571X5H
Public MeSH Note: 2016; DASATINIB was indexed under PYRIMIDINES and THIAZOLES 2004-2015
History Note: 2016 (2004)
DeCS ID: 55904
Unique ID: D000069439
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2016/01/01
Date of Entry: 2015/07/01
Revision Date: 2016/05/28
Dasatinib - Preferred
Concept UI M0470497
Scope note A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
Preferred term Dasatinib
Entry term(s) N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel - Narrower
Concept UI M0498440
Preferred term Sprycel
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide - Narrower
Concept UI M0517195
Preferred term (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
BMS 354825 - Narrower
Concept UI M0470498
Preferred term BMS 354825
Entry term(s) 354825, BMS
BMS-354825
BMS354825



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey